← Back to Search

Neuromodulation

TMS for Depression (TMS-LLD Trial)

N/A
Recruiting
Research Sponsored by University of New Mexico
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 3 post-treatment assessment
Awards & highlights

Summary

This trial aims to improve the effectiveness of a non-invasive brain stimulation technique for elderly patients with late-life depression by using imaging technology to precisely target brain areas involved in mood regulation. The goal is to provide a safer and more effective treatment option for those who have not responded well to traditional therapies. This brain stimulation technique has been studied for many years as a treatment for depression, showing potential benefits especially in older patients.

Who is the study for?
This trial is for English-speaking individuals aged 60-79 with major depressive disorder diagnosed by a psychiatrist, currently experiencing a depressive episode. Excluded are pregnant women, those with bipolar or psychotic disorders, recent hospitalization, neurosurgery history, ECT in the last three months, MRI contraindications, substance abuse within three months, seizure history or neurological disorders.
What is being tested?
The study tests how to improve transcranial magnetic stimulation (TMS), an existing treatment for late-life depression. It uses fMRI to personalize TMS targeting and assess its effectiveness in an open-label setting where all participants receive the intervention.
What are the potential side effects?
While not specified here, common side effects of rTMS may include headache or scalp discomfort at the site of stimulation. Rarely it can cause seizures or hearing loss if ear protection isn't used during treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 3 post-treatment assessment
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 3 post-treatment assessment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Anterior Cingulate Cortex (ACC) Connectivity
Secondary study objectives
Depression Severity

Trial Design

1Treatment groups
Experimental Treatment
Group I: rTMSExperimental Treatment1 Intervention
Subjects will receive rTMS to the area of the DLPFC most anticorrelated with the ACC.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
rTMS
2016
Completed Phase 3
~840

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Transcranial Magnetic Stimulation (TMS) is a non-invasive treatment for depression that uses magnetic fields to stimulate nerve cells in the brain, particularly targeting areas involved in mood regulation. Enhanced by functional MRI (fMRI), TMS can be more precisely targeted to the affected brain regions, potentially increasing its efficacy. This matters for depression patients because it offers a treatment option that can be tailored to their specific neural activity patterns, potentially leading to better outcomes with fewer side effects compared to traditional pharmacotherapy. Understanding these mechanisms helps patients and clinicians make informed decisions about incorporating TMS into their treatment plans, especially for those who have not responded to conventional treatments.
[Historical review and recent research trends of the antidepressant repetitive transcranial magnetic stimulation (rTMS)].

Find a Location

Who is running the clinical trial?

The Mind Research NetworkOTHER
26 Previous Clinical Trials
2,446 Total Patients Enrolled
1 Trials studying Depression
62 Patients Enrolled for Depression
University of New MexicoLead Sponsor
384 Previous Clinical Trials
3,524,632 Total Patients Enrolled
15 Trials studying Depression
2,690 Patients Enrolled for Depression

Media Library

rTMS (Neuromodulation) Clinical Trial Eligibility Overview. Trial Name: NCT04543773 — N/A
Depression Research Study Groups: rTMS
Depression Clinical Trial 2023: rTMS Highlights & Side Effects. Trial Name: NCT04543773 — N/A
rTMS (Neuromodulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04543773 — N/A
~0 spots leftby Dec 2024